Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Capecitabine and Oxaliplatin for Resectable Colorectal Liver Metastases
NCT00070265Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2003
- Primary completion
- Sep 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Aug 2003; status: terminated.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00070265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070265.